Lantheus (NasdaqGM:LNTH) Q4 2025 Earnings call February 26, 2026 08:00 AM ET Company ParticipantsAmanda Morgan - Chief Commercial OfficerAnthony Petrone - Managing Director of Equity ResearchKarishma Raghuram - Biotechnology Equity Research AssociateLarry Solow - Managing DirectorMark Kinarney - VP of Investor RelationsMary Anne Heino - Executive Chairperson and Interim CEORobert Marshall - CFO and TreasurerYuan Zhi - Managing DirectorConference Call ParticipantsAndy Hsieh - Biotechnology AnalystJustin Wals ...

Lantheus (NasdaqGM:LNTH) Q4 2025 Earnings call February 26, 2026 08:00 AM ET Company ParticipantsAmanda Morgan - Chief Commercial OfficerAnthony Petrone - Managing Director of Equity ResearchKarishma Raghuram - Biotechnology Equity Research AssociateLarry Solow - Managing DirectorMark Kinarney - VP of Investor RelationsMary Anne Heino - Executive Chairperson and Interim CEORobert Marshall - CFO and TreasurerYuan Zhi - Managing DirectorConference Call ParticipantsAndy Hsieh - Biotechnology AnalystJustin Wals ...

Lantheus (NasdaqGM:LNTH) Q4 2025 Earnings call February 26, 2026 08:00 AM ET Speaker10Good morning. Welcome to Lantheus' fourth quarter and full year 2025 conference call. All lines have been placed on mute. This call is being recorded. A replay will be available in the Investors section of the company's website approximately two hours after the completion of the call, and will be archived for at least 30 days. I'll now turn the call over to Mark Guarnieri, Vice President of Investor Relations. Mark?Speaker ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K (Mark One) ☑ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2025 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 001-36569 LANTHEUS HOLDINGS, INC. (Exact name of registrant as specified in its charter) | Delaware | 35-2318913 | | --- | ...

© 2026 Lantheus. All rights reserved. Agenda Lantheus Fourth Quarter & Full Year 2025 Results FEBRUARY 26, 2026 Highlights and Business Update Commercial Update Financial Update Closing Remarks Q&A SPEAKERS Mary Anne Heino Executive Board Chair & CEO © 2026 Lantheus. All rights reserved. 2 Bob Marshall CFO and Treasurer Amanda Morgan Chief Commercial Officer Mark Kinarney Vice President, Investor Relations Safe Harbor Statements Cautionary Statement Regarding Forward-Looking Statements This document contain ...

Exhibit 99.1 Lantheus Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update BEDFORD, Mass., February 26, 2026 (GLOBE NEWSWIRE) -- Lantheus Holdings, Inc. (Lantheus or the Company) (NASDAQ: LNTH), the leading radiopharmaceutical-focused company committed to enabling clinicians to Find, Fight and Follow disease to deliver better patient outcomes, today reported financial results for its fourth quarter and full year ended December 31, 2025. "In 2025 we accomplished the import ...

Worldwide revenue of $406.8 million and $1.54 billion for the fourth quarter and full year 2025GAAP fully diluted earnings per share of $0.82 and $3.41 for the fourth quarter and full year 2025Adjusted fully diluted earnings per share of $1.67 and $6.08 for the fourth quarter and full year 2025Repurchased $100 million of shares of common stock in the fourth quarter pursuant to the previously announced stock repurchase plan that was approved by the Board in July 2025Company announced today that it is sharpen ...

BEDFORD, Mass., Feb. 24, 2026 (GLOBE NEWSWIRE) -- Lantheus Holdings, Inc. (“Lantheus” or the “Company”) (NASDAQ: LNTH), the leading radiopharmaceutical-focused company dedicated to helping clinicians Find, Fight, and Follow disease to deliver better patient outcomes, today announced Mary Anne Heino, Executive Chairperson and Chief Executive Officer, will present at the following investor conferences. TD Cowen 46th Annual Health Care ConferenceMarch 3, 2026 at 11:10 a.m. ETLeerink Global Healthcare Conferenc ...

Core Insights - Lantheus Holdings, Inc. (NASDAQ:LNTH) is recognized as one of the seven cheap pharmaceutical stocks to buy according to hedge funds, ranking fourth on the list [2] - TD Cowen has lowered its price target for LNTH from $80 to $75 while maintaining a Buy rating, reflecting adjustments in their financial model ahead of the company's fourth-quarter results [2][8] - The company has completed the divestiture of its Single Photon Emission Computed Tomography (SPECT) business to SHINE Technologies, which may allow it to focus on more profitable growth areas [3] Company Strategy - Lantheus is prioritizing the growth of its commercial portfolio in PET radiodiagnostics and microbubble products for contrast-enhanced ultrasound procedures [4] - The company plans to invest in and develop its pipeline of radiopharmaceuticals to support long-term growth in precision imaging and targeted treatments [4] - Lantheus aims to leverage its expertise in nuclear medicine to create innovative diagnostic and therapeutic solutions for patients [4][5]

Core Viewpoint - Lantheus Holdings, Inc. will host a conference call and webcast to discuss its financial and operating results for Q4 and the full year of 2025 on February 26, 2026 [1]. Group 1: Conference Call Details - The conference call and webcast will take place at 8:00 a.m. ET on February 26, 2026 [1]. - Participants can register online to access the conference call or webcast, with a recommendation to register fifteen minutes in advance to avoid delays [2]. - A replay of the webcast will be available approximately two hours after its completion and will be archived for at least 30 days [2]. Group 2: Company Overview - Lantheus is a leading company focused on radiopharmaceuticals, providing solutions that help clinicians in disease detection and management [3]. - The company has been in operation for 70 years and is headquartered in Massachusetts, with additional offices in New Jersey, Canada, Germany, Sweden, Switzerland, and the United Kingdom [3].